id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC5034095 | core_pubmed_pmc | A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy | A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy Abstract Abstract Introduction Vaginal tenofovir (TFV) 1% gel may reduce incident HIV-1 and herpes simplex virus 2 infection. Pregnancy may increase risk of HIV acquisition, and incident HIV in pregnancy potentiates ... |
PMC4262094 | core_pubmed_pmc | A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects | A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects Abstract Aims We investigated the relative pharmacokinetics, pharmacodynamics, and ... |
PMC5525553 | core_pubmed_pmc | A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs | A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs Abstract Purpose To compare the efficacy of microneedle-delivered suprachoroidal (SC) pazopanib to intravitreal (Ivit) delivery of pazopanib, bevacizumab, or a fusion protein hI-con1 versus vehicle controls on choro... |
PMC12735885 | core_pubmed_pmc | A Systematic Review and Meta-Analysis of Doxazosin Pharmacokinetics in Healthy and Diseased Populations | A Systematic Review and Meta-Analysis of Doxazosin Pharmacokinetics in Healthy and Diseased Populations Abstract Abstract Background: Doxazosin, an α 1 -adrenergic antagonist, is commonly used in the management of hypertension and benign prostatic hyperplasia (BPH). Pharmacokinetic (PK) variability across populations m... |
PMC7529331 | core_pubmed_pmc | Pharmacokinetic, pharmacodynamic, and neurochemical investigations of lamotrigine‐pentylenetetrazole kindled mice to ascertain it as a reliable model for clinical drug‐resistant epilepsy | Pharmacokinetic, pharmacodynamic, and neurochemical investigations of lamotrigine‐pentylenetetrazole kindled mice to ascertain it as a reliable model for clinical drug‐resistant epilepsy Abstract Abstract Background Pentylenetetrazole kindling has long been used for the screening of investigational antiseizure drugs. T... |
PMC4260137 | core_pubmed_pmc | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Abstract The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives to long-standing standards of care that include low-molecular-weight heparin and warfarin. The development of apixaban reflects a strategy to optimize the clinical pharmacolo... |
PMC11064047 | core_pubmed_pmc | Tailoring of Bilosomal Nanogel for Augmenting the Off-Label Use of Sildenafil Citrate in Pediatric Pulmonary Hypertension | Tailoring of Bilosomal Nanogel for Augmenting the Off-Label Use of Sildenafil Citrate in Pediatric Pulmonary Hypertension Abstract Pediatric pulmonary hypertension is a serious syndrome with significant morbidity and mortality. Sildenafil is widely used off-label in pediatric patients with pulmonary arterial hypertensi... |
PMC7713806 | core_pubmed_pmc | Accuracy assessment of a PION TCI pump based on international standards | Accuracy assessment of a PION TCI pump based on international standards Abstract Abstract Background Inaccuracies associated with target-controlled infusion (TCI) delivery systems are attributable to both software and hardware issues, as well as pharmacokinetic variability. However, little is known about the inaccuracy... |
PMC11465679 | core_pubmed_pmc | Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies | Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies Abstract Abstract Background SHR-1707 is a novel humanized anti-Aβ IgG1 monoclonal antibody that binds to Aβ fibrils and mo... |
PMC9660540 | core_pubmed_pmc | Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors | Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors Abstract Abstract Purpose: To evaluate AZD4635, an adenosine A 2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with a... |
PMC11744960 | core_pubmed_pmc | Urinary phthalate metabolites associated with increased prevalence of gallstone disease in U.S. adults: data from the NHANES study | Urinary phthalate metabolites associated with increased prevalence of gallstone disease in U.S. adults: data from the NHANES study Abstract Background Phthalate exposure has been hypothesized to influence cholesterol metabolism and gallstone pathogenesis, but previous studies are limited. We aimed to examine the associ... |
PMC8346919 | core_pubmed_pmc | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective Na V 1.8 Inhibitor, in Healthy Male Adults | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective Na V 1.8 Inhibitor, in Healthy Male Adults Abstract Abstract Objective To evaluate the analgesic potential, safety, tolerability, and pharmacokinetics of VX-150, a pro-drug of a... |
PMC9702083 | core_pubmed_pmc | Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections | Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections Abstract The emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae is seriously threatening the treatment and control of gonorrhea globally. Novel tr... |
PMC3640601 | core_pubmed_pmc | Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor | Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor Abstract Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute c... |
PMC3899448 | core_pubmed_pmc | Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects | Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects Abstract Abstract Background and Objectives Rotigotine is a dopamine receptor agonist with activity across the D 1 through to D 5 receptors as well as select serotonergic and adrenergic sites; continuous... |
PMC12399214 | core_pubmed_pmc | Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects | Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects Abstract Invasive fungal infections (IFIs) have become prominent global health threats, escalating the burden on public health systems. The increasing occurrence of invasive fungal infections is due primarily to the extensive application of ... |
PMC4269818 | core_pubmed_pmc | Ibuprofen Sodium Is Absorbed Faster than Standard Ibuprofen Tablets: Results of Two Open-Label, Randomized, Crossover Pharmacokinetic Studies | Ibuprofen Sodium Is Absorbed Faster than Standard Ibuprofen Tablets: Results of Two Open-Label, Randomized, Crossover Pharmacokinetic Studies Abstract Abstract Background A novel ibuprofen (IBU) formulation, Advil ® Film-Coated Tablets (IBU Na ), was developed. Objective Pharmacokinetic comparison of IBU Na versus othe... |
PMC7214649 | core_pubmed_pmc | Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin | Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin Abstract Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro . To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐... |
PMC8374068 | core_pubmed_pmc | A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan | A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan Abstract The numerous beneficial health outcomes associated with the use of metformin to treat patients with type 2 diabetes (T2DM), together with data from pre-clinical studies in animals includ... |
PMC11942484 | core_pubmed_pmc | A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control | A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control Abstract Fibroblast growth factor 21 (FGF21), a hormone-like protein, plays a crucial role in enhancing glucose and lipid metabolism, offering promising therapeutic avenues for condition... |
PMC11787782 | core_pubmed_pmc | Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy | Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy Abstract Abstract Purpose Warfarin is an anticoagulant drug widely used for treating thromboembolism-related conditions. The main challenge with this drug is the high variability ... |
PMC6897292 | core_pubmed_pmc | Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll ® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico , In Vitro , and Human Biomonitoring Data | Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll ® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico , In Vitro , and Human Biomonitoring Data Abstract A physiologically based pharmacokinetic model for Hexamoll ® diisono... |
PMC8519033 | core_pubmed_pmc | Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity | Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity Abstract Summary Background Obesity in adolescence presents a major public health challenge, often leading to obesity in adulthood with associated chronic disease. Objectives This study aimed to perform a population pharmacokinetic and expos... |
PMC7612404 | core_pubmed_pmc | Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy | Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy Abstract Abstract Aim Dolutegravir is associated with more weight gain than efavirenz in people starting antiretroviral therapy (ART). We investigated the concentration-response relationships of e... |
PMC12130374 | core_pubmed_pmc | Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors | Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors Abstract Abstract Introduction A combination of targeted anticancer drugs with cytotoxic therapy can potentially overcome multidrug resistance. The multi-target kinase inhibitor sorafenib demonstrates synergistic... |
PMC6937755 | core_pubmed_pmc | A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects | A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects Abstract Abstract Background/objective FKB327 is a biosimilar of the ... |
PMC6743242 | core_pubmed_pmc | A Review of Controlled Drug Delivery Systems Based on Cells and Cell Membranes | A Review of Controlled Drug Delivery Systems Based on Cells and Cell Membranes Abstract Novel drug delivery systems have ameliorated drugs’ pharmacokinetics and declined undesired ramifications while led to a better patient compliance by extending the time of release. In fact, although there has been a multitude of enc... |
PMC8070284 | core_pubmed_pmc | Pharmacokinetic Characterization of LW6, a Novel Hypoxia-Inducible Factor-1α (HIF-1α) Inhibitor in Mice | Pharmacokinetic Characterization of LW6, a Novel Hypoxia-Inducible Factor-1α (HIF-1α) Inhibitor in Mice Abstract Abstract LW6, an (aryloxyacetylamino)benzoic acid derivative, was recently identified to be an inhibitor of hypoxia-inducible factor-1α (HIF-1α), which is an attractive target for cancer therapeutics. Althou... |
PMC6273138 | core_pubmed_pmc | Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5′-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes | Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5′-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes Abstract Abstract Aschantin is a bioactive neolignan found in Magnolia flos with antiplasmodial, Ca 2+ -antagonistic, platelet activating factor-antagonistic, and chemopreventi... |
PMC12517267 | core_pubmed_pmc | Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries | Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries Abstract SUMMARY BACKGROUND Routinely, a 400-mg tablet of moxifloxacin is used in children with rifampicin-resistant TB (RR-TB), but it has very poor acceptability. We describe the acceptability of a 100-mg disp... |
PMC6182726 | core_pubmed_pmc | Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals | Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals Abstract Abstract The physiologically based pharmacokinetic (PBPK) models allow for pre... |
PMC10761441 | core_pubmed_pmc | Kinetically-derived maximal dose (KMD) indicates lack of human carcinogenicity of ethylbenzene | Kinetically-derived maximal dose (KMD) indicates lack of human carcinogenicity of ethylbenzene Abstract Abstract The kinetically-derived maximal dose (KMD) is defined as the maximal external dose at which kinetics are unchanged relative to lower doses, e.g., doses at which kinetic processes are not saturated. Toxicity ... |
PMC10215112 | core_pubmed_pmc | The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses | The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses Abstract Simple Summary Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed in equine practice for a variety of painful or inflammatory conditions. This review discusses the clinical pharmaco... |
PMC5094513 | core_pubmed_pmc | Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy | Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy Abstract Abstract Palmitoylethanolamide (PEA) has been suggested to have useful analgesic properties and to be devoid of unwanted effects. Here, we have examined critically this contention, and discussed available data concerning the... |
PMC8712478 | core_pubmed_pmc | Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review | Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review Abstract Abstract Recently, sleep has been recognized as a crucial factor for health and longevity. The daily sleep/wake cycle provides the basis of biorhythm, which controls whole-body homeostasis and homeodynamics. Sl... |
PMC12414074 | core_pubmed_pmc | Malnutrition and Its Effect on Drug Pharmacokinetics: A Clinical Perspective | Malnutrition and Its Effect on Drug Pharmacokinetics: A Clinical Perspective Abstract Abstract Malnutrition significantly alters the pharmacokinetics of medications, particularly in vulnerable populations such as children, pregnant women, elderly individuals, and individuals in low- and middle-income countries. These p... |
PMC6765692 | core_pubmed_pmc | Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults | Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults Abstract Background and Objective This study was performed in healthy Chinese subjects to evaluate the safety and pharmacokinetic/pharmacodynamic characteristics of a novel injection for... |
PMC9221162 | core_pubmed_pmc | Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial | Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial Abstract Abstract Simple Summary Low-dose continuous oral chemotherapy may work together with targeted tyrosine kinase inhibitors to target a cancer’s ability to promote new bl... |
PMC11347695 | core_pubmed_pmc | Under-representation of older Indian persons with cancer in clinical trials | Under-representation of older Indian persons with cancer in clinical trials Abstract Abstract Objective Older patients with cancer have traditionally been under-represented in global clinical trials. There are no data from India regarding this issue. Methods and analysis This was a retrospective analysis done at our in... |
PMC3449383 | core_pubmed_pmc | E-Pharmacophore mapping and docking studies on Vitamin D receptor (VDR) | E-Pharmacophore mapping and docking studies on Vitamin D receptor (VDR) Abstract Abstract Small structured chemical molecules are importance in the field of molecular medicine since their pharmacokinetic and pharmacodynamic properties are predictable and because of its ability to bind with target molecules and execute ... |
PMC9876276 | core_pubmed_pmc | The pharmacokinetics and pharmacodynamics of cefquinome against Streptococcus agalactiae in a murine mastitis model | The pharmacokinetics and pharmacodynamics of cefquinome against Streptococcus agalactiae in a murine mastitis model Abstract Abstract Cefquinome is a new generation cephalosporin that is effective in the treatment of mastitis in animals. In this study, we evaluated the associations between the specific pharmacokinetics... |
PMC2889733 | core_pubmed_pmc | Preclinical PK and PD Studies on 2′- O -Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model | Preclinical PK and PD Studies on 2′- O -Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model Abstract Abstract Antisense oligonucleotides (AONs) are being developed as RNA therapeutic molecules for Duchenne muscular dystrophy. For oligonucleotides with the 2′- O -methyl-phosphorothioate (2OMePS... |
PMC7038312 | core_pubmed_pmc | Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies | Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies Abstract Tuberculosis (TB) drug, regimen, and vaccine development rely heavily on preclinical animal experiments, and quantification of bacterial and immune response dynamics is essential for understandin... |
PMC4745832 | core_pubmed_pmc | Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis | Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis Abstract Abstract Background Limited data are available on mesalamine (5-aminosalicylic acid; 5-ASA) use in pediatric ulcerative colitis (UC). Aim To evaluate pharmacokinetic and safety profile... |
PMC11718548 | core_pubmed_pmc | Microneedles as a Promising Technology for Disease Monitoring and Drug Delivery: A Review | Microneedles as a Promising Technology for Disease Monitoring and Drug Delivery: A Review Abstract The delivery of molecules, such as DNA, RNA, peptides, and certain hydrophilic drugs, across the epidermal barrier poses a significant obstacle. Microneedle technology has emerged as a prominent area of focus in biomedica... |
PMC10719490 | core_pubmed_pmc | A first‐in‐human phase I study of SHR‐1906, a humanized monoclonal antibody against connective tissue growth factor, in healthy participants | A first‐in‐human phase I study of SHR‐1906, a humanized monoclonal antibody against connective tissue growth factor, in healthy participants Abstract Abstract New therapeutic targets and drugs are urgently needed to halt the fibrosing process in idiopathic pulmonary fibrosis (IPF). SHR‐1906 is a novel fully humanized m... |
PMC9633485 | core_pubmed_pmc | Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N -oxide | Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N -oxide Abstract Purpose Voriconazole is a therapeutically challenging antifungal drug associated with high interindividual pharmacokinetic variability. As a prerequisite to performing clinical trials using t... |
PMC7220402 | core_pubmed_pmc | Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C 0 and AUC | Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C 0 and AUC Abstract Abstract We hypothesized that area under the concentration time curve (AUC (0-12) ) is more accurate pharmacokinetic predictor vs trough level of mycophenolic acid (C 0 ). Study was performed at the Univ... |
PMC9750107 | core_pubmed_pmc | Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study | Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study Abstract Background: Despite progress in treating homozygous familial hypercholesterolemia, most patients do not achieve low-density lipoprotein cholesterol (LDL-C) target... |
PMC5613062 | core_pubmed_pmc | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors Abstract Summary Background Combinations of molecularly targeted agents may provide optimal anti-tumor activity and improve clinical outcomes for patients with advanced cancers. Selumetini... |
PMC7591420 | core_pubmed_pmc | Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer | Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer Abstract Background Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. Objective This phase 1b trial investigated the safety, maximum tolerated ... |
PMC5610536 | core_pubmed_pmc | Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects | Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects Abstract ABSTRACT Drug-drug interactions between antiretroviral medications and rifampin complicate the treatment of HIV and tuberculosis coinfection. This study evaluated the effect of rifampin on the pharmacokinetics of or... |
PMC9599027 | core_pubmed_pmc | Individual Pharmacotherapy Management (IPM)—IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy | Individual Pharmacotherapy Management (IPM)—IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy Abstract Abstract Antimicrobial therapy is often a life-saving medical intervention for inpatients and outpatients. Almost all medical ... |
PMC6025223 | core_pubmed_pmc | A Phase II Study of Pelareorep (REOLYSIN ® ) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma | A Phase II Study of Pelareorep (REOLYSIN ® ) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma Abstract Abstract Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with na... |
PMC12934543 | core_pubmed_pmc | Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer | Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer Abstract Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with hom... |
PMC3467880 | core_pubmed_pmc | Pharmacodynamic responses of exogenous epinephrine during mandibular third molar surgery | Pharmacodynamic responses of exogenous epinephrine during mandibular third molar surgery Abstract Abstract Background: The systemic effects attributable to the injection of dental local anesthetic solutions have been the subject of discussion for many years. Aim and Objective: The aim of the present study was to invest... |
PMC8307098 | core_pubmed_pmc | Synthesis and Bioinformatic Characterization of New Schiff Bases with Possible Applicability in Brain Disorders | Synthesis and Bioinformatic Characterization of New Schiff Bases with Possible Applicability in Brain Disorders Abstract (1) Background: The research aims to find new treatments for neurodegenerative diseases, in particular, Alzheimer’s disease. (2) Methods: This article presents a bioinformatics and pathology study of... |
PMC8810887 | core_pubmed_pmc | Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT | Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT Abstract Abstract Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PK) and metabolism of citrate in liver failure patients who requi... |
PMC11035515 | core_pubmed_pmc | Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism | Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism Abstract Abstract Background and Objective Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is the opioid inactive dextro-isomer of racemic methadone. Esmethadone is a low potency N-me... |
PMC6842130 | core_pubmed_pmc | Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats | Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats Abstract Abstract Purpose: The study establishes normative data of tear volume (TV) and tear turnover rate (TTR) in healthy dogs and cats, 2 species commonly used for translational research in ophthalmology. Methods: Thirty-six dogs ... |
PMC10836316 | core_pubmed_pmc | First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity | First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity Abstract Abstract Background Minnelide is a water-soluble prodrug of triptolide. Triptolide is an anticancer agent that targets cancer resistance through sever... |
PMC11897840 | core_pubmed_pmc | Prolonged Elimination of Lamotrigine After Suicidal Overdose: A Case Report | Prolonged Elimination of Lamotrigine After Suicidal Overdose: A Case Report Abstract Lamotrigine (LTG) is an antiepileptic drug that stabilizes neuronal membranes by inhibiting excitatory neurotransmitter release, thereby reducing neuronal excitation. Various factors can contribute to its metabolic dysfunction. A 22-ye... |
PMC4270037 | core_pubmed_pmc | Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms | Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms Abstract Abstract Background Despite use of a lower mycophenolate dose in Thai kidney transplant patients, acceptable graft and patient outcomes can be achieved. We therefore examine... |
PMC5788216 | core_pubmed_pmc | Development of Nanoemulsion Based Gel Loaded with Phytoconstituents for the Treatment of Urinary Tract Infection and in Vivo Biodistribution Studies | Development of Nanoemulsion Based Gel Loaded with Phytoconstituents for the Treatment of Urinary Tract Infection and in Vivo Biodistribution Studies Abstract Purpose: A nanoemulsion based gel containing Polyphenon 60 (P60) and cranberry (CRB) has been developed to deliver via intravaginal route for the treatment of uri... |
PMC5887840 | core_pubmed_pmc | Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status | Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status Abstract Abstract The objectives of this analysis were to develop a population pharmacokinetics (PK) model of durvalumab, an anti‐PD‐L1 antibody, and quantify the impact of baseline and time‐varyi... |
PMC6863819 | core_pubmed_pmc | Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis | Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis Abstract Abstract Progressive familial intrahepatic cholestasis (PFIC), a rare inherited disorder, progresses to liver failure in childhood. We have shown that sodium 4-phenylbutyrate (Na... |
PMC10671645 | core_pubmed_pmc | The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution—A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling | The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution—A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling Abstract A permeability-limited physiologically bas... |
PMC12103781 | core_pubmed_pmc | Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer | Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer Abstract Background OMT-110 is a repositioned drug candidate for the treatment of metastatic colorectal cancer (mCRC). This phase I study aimed to determine the appropriate dose... |
PMC4288327 | core_pubmed_pmc | Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling | Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling Abstract Abstract Physiologically based pharmacokinetic (PBPK) models integrate both chemical- and system-specific information into a mathematical framework, offering a mechanistic approach to predict the internal dose metrics ... |
PMC5565246 | core_pubmed_pmc | Potential drug–drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital | Potential drug–drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital Abstract Purpose Although the concomitant use of multiple drugs often increases therapeutic effectiveness, certain combinations result in unwanted drug–drug interactions (DDIs). Most interactions g... |
PMC11289455 | core_pubmed_pmc | JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans | JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans Abstract The interleukin (IL)-23 pathway is a pathogenic driver in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Currently, no oral therapeutics s... |
PMC6044797 | core_pubmed_pmc | Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs | Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs Abstract Abstract Investigation into the pharmacokinetic profile of esomeprazole was conducted using eight healthy dogs after intravenous (IV) and oral (po) administration in a two-part randomized crossover study. The dogs we... |
PMC9393138 | core_pubmed_pmc | The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies | The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies Abstract Abstract Background Critical appraisal aids in assessing the quality of scientific literature, which is central to the practice of evidence-based medicine. Several tools and guidelines are available... |
PMC7292875 | core_pubmed_pmc | Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug | Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug Abstract Abstract In contrast to plasma pharmacokinetics, intratumoral pharmacokinetics of doxorubicin (DOX) determines its spatial anti-tumoral activity. Three-dimensional multicellular layers ... |
PMC6668111 | core_pubmed_pmc | Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B | Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B Abstract Abstract Background Immunotherapeutic approaches designed to augment T and B cell mediated killing of tumor cells has met with clinical success in recent years suggesting tremendous potential for treatment ... |
PMC10800708 | core_pubmed_pmc | Efficacies and ADME properties of redox active methylene blue and phenoxazine analogues for use in new antimalarial triple drug combinations with amino-artemisinins | Efficacies and ADME properties of redox active methylene blue and phenoxazine analogues for use in new antimalarial triple drug combinations with amino-artemisinins Abstract Abstract Efforts to develop new artemisinin triple combination therapies effective against artemisinin-tolerant strains of Plasmodium falciparum b... |
PMC10681508 | core_pubmed_pmc | PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor | PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor Abstract Abstract The optimal dose for targeted oncology therapeutics is often not the maximum tolerated dose. Pharmacokinetic/pharmacodynamic (PK/PD) modeling can be an effective tool to integrate cli... |
PMC9587772 | core_pubmed_pmc | Ask Your Provider About Cannabis: Increasing Nurse Practitioner Knowledge and Confidence | Ask Your Provider About Cannabis: Increasing Nurse Practitioner Knowledge and Confidence Abstract Abstract Introduction: Nurse practitioners (NPs) are authorizing providers for medical cannabis in many states, and may serve as a primary care clinician. We report findings from a nationally distributed 2-h continuing edu... |
PMC10585000 | core_pubmed_pmc | Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count | Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count Abstract Clozapine is effective at reducing symptoms of treatment-resistant schizophrenia, but it can also induce several adverse outcomes including neutropenia and agranu... |
PMC10792358 | core_pubmed_pmc | A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer | A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer Abstract Abstract Purpose: Endocrine-based therapy is the initial primary treatment option for hormone receptor–positive and human epidermal growth factor receptor 2-ne... |
PMC4329422 | core_pubmed_pmc | Clinical Pharmacology of Paracetamol in Neonates: A Review | Clinical Pharmacology of Paracetamol in Neonates: A Review Abstract Paracetamol is commonly used to control mild-to-moderate pain or to reduce opioid exposure as part of multimodal analgesia, and is the only compound recommended to treat fever in neonates. Paracetamol clearance is lower in neonates than in children and... |
PMC10304400 | core_pubmed_pmc | Prevalence and Risk Factors Associated with Potentially Inappropriate Prescribing According to STOPP-2 Criteria among Discharged Older Patients—An Observational Retrospective Study | Prevalence and Risk Factors Associated with Potentially Inappropriate Prescribing According to STOPP-2 Criteria among Discharged Older Patients—An Observational Retrospective Study Abstract Pharmacokinetic and pharmacodynamic changes associated with old age, along with multimorbidity and polypharmacy might lead to inap... |
PMC9003587 | core_pubmed_pmc | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients Abstract Summary Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of ... |
PMC7689089 | core_pubmed_pmc | Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma | Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma Abstract Abstract Background and purpose Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple canc... |
PMC9599747 | core_pubmed_pmc | Association of SLC22A1 , SLC22A2 , SLC47A1 , and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients | Association of SLC22A1 , SLC22A2 , SLC47A1 , and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients Abstract Abstract Response to metformin, first-line therapy for type 2 diabetes mellitus (T2DM), exists interindividual variation. Considering that transporters belonging to the solute carrier (SLC... |
PMC6156772 | core_pubmed_pmc | Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory | Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory Abstract Purpose Physiologically-based pharmacokinetic (PBPK) models are essential in drug development, but require parameters that are not always obtainab... |
PMC9539103 | core_pubmed_pmc | Pharmacokinetics of butorphanol following intravenous and intramuscular administration in donkeys: A preliminary study | Pharmacokinetics of butorphanol following intravenous and intramuscular administration in donkeys: A preliminary study Abstract Abstract The pharmacokinetics of butorphanol after intravenous (IVB) and intramuscular (IMB) administration in donkeys were determined in this preliminary study. Healthy male gelded donkeys ( ... |
PMC3157216 | core_pubmed_pmc | Feasibility of Imaging Myelin Lesions in Multiple Sclerosis | Feasibility of Imaging Myelin Lesions in Multiple Sclerosis Abstract The goal of this study was to provide a feasibility assessment for PET imaging of multiple sclerosis (MS) lesions based on their decreased myelin content relative to the surrounding normal-appearing brain tissue. The imaging agent evaluated for this p... |
PMC11144913 | core_pubmed_pmc | Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy | Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy Abstract Combination therapies can enhance the sensitivity of cancer to drugs, lower drug doses, and reduce side effects in cancer treatment. However, differences in the physicochemical properties and pharmacokineti... |
PMC3409044 | core_pubmed_pmc | Multiple concurrent collagenase clostridium histolyticum injections to dupuytren’s cords: an exploratory study | Multiple concurrent collagenase clostridium histolyticum injections to dupuytren’s cords: an exploratory study Abstract Abstract Background Dupuytren’s contracture (DC) is a progressive fibroproliferative disorder characterized by development of nodules and collagen cords within the palmar fascia of the hand. Collagena... |
PMC3889701 | core_pubmed_pmc | Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban | Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban Abstract Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma concentrations being reached 2–4 h after tablet intake. Oral... |
PMC3828005 | core_pubmed_pmc | Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development | Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development Modeling Different PK Model Types: Classical Vs. PBPK Models Mathematical models are frequently used to help understand the PK of drugs following intravenous (i.v.) and oral dosing in animals and humans. Models describing... |
PMC7707836 | core_pubmed_pmc | Challenges in the management of chronic hypoparathyroidism | Challenges in the management of chronic hypoparathyroidism Abstract Abstract The first adjunctive hormone therapy for chronic hypoparathyroidism, recombinant human parathyroid hormone (1–84) (rhPTH(1–84)) was approved by the FDA in January 2015. Since the approval of rhPTH(1–84), growing interest has developed in other... |
PMC8479189 | core_pubmed_pmc | Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer | Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer Abstract Background Zimberelimab (GLS-010) is a novel fully human monoclonal immunoglobulin G4 (IgG4) against the programmed cell death-1 (PD-1) receptor. Aim To evaluate the affinity, compet... |
PMC11567709 | core_pubmed_pmc | Patiromer Does Not Alter Tacrolimus Pharmacokinetics in Kidney Transplant Recipients When Administered Three Hours Post–Tacrolimus | Patiromer Does Not Alter Tacrolimus Pharmacokinetics in Kidney Transplant Recipients When Administered Three Hours Post–Tacrolimus Abstract Background. Hyperkalemia is common in kidney transplant (KTx) recipients. Patiromer, a potassium-binding polymer used to treat acute and chronic hyperkalemia, has the potential to ... |
PMC11620509 | core_pubmed_pmc | How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children | How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children Abstract ABSTRACT Standard dosing could fail to achieve adequate systemic concentrations in ICU children or may lead to toxicity in children with acute kidney injury. The population pharmac... |
PMC12501462 | core_pubmed_pmc | Abelacimab for Acute Pulmonary Embolism: Translating Dual FXI/XIa Inhibition from Mechanism to Clinical Prospects | Abelacimab for Acute Pulmonary Embolism: Translating Dual FXI/XIa Inhibition from Mechanism to Clinical Prospects Abstract Abstract Acute pulmonary embolism (PE) remains a life-threatening condition. A critical therapeutic dilemma exists for a significant proportion of patients at high bleeding risk（approximately 30%-5... |
PMC4858031 | core_pubmed_pmc | Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing | Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing Abstract Background Levetiracetam is an anticonvulsant used for control of canine epilepsy. An extended release preparation should improve dosing convenience. Objectives To determine the disposition of extended release levetir... |
PMC8476547 | core_pubmed_pmc | Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers | Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers Abstract Clinical trials repurposing peroxisome proliferator-activated receptor-gamma (PPARγ) agonists as anticancer agents have exhibited lackluster efficacy across a variety of tumor types. Here, w... |
PMC12358302 | core_pubmed_pmc | Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study | Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study Abstract ABSTRACT In patients with recurrent advanced ovarian cancer, there is a need for companion tests to guide the development of innovative chemotherapy‐free treatmen... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.